Lung cancer trials in Poland

In Poland 114 Also abroad 2733

114 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 2/3Taking people
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Where
Bydgoszcz, Lublin, Poznan
Age
18 years and over
People
500 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07100080
Phase 3Taking people
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Katowice, Kielce, Krakow, Lodz, Lublin, Opole, Radom, Tomaszow Mazowiecki, Wroclaw
Age
18 years and over
People
1,410 worldwide
Run by
Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01
Phase 2Taking people
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Where
Gdansk, Lodz, Lublin, Wroclaw
Age
18 years and over
People
120 worldwide
Run by
Pfizer
See details and how to joinNCT07489066 · EU 2025-524825-42-00
Phase 2Taking people
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Where
Gdansk, Koszalin, Poznan, Warsaw
Age
18 years and over
People
144 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06780098 · EU 2024-518839-11-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Cracow, Gdansk, Lublin, Olsztyn, Poznan, Radom, Warsaw, Wieliszew, Wilkowice, Wroclaw
Age
18 years and over
People
282 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00 · EU 2024-518365-10-00
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Cracow, Gdansk, Lublin, Poznan, Sosnowiec, Tomaszow Mazowiecki, Warsaw
Age
18 years and over
People
490 worldwide
Run by
AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00
Phase 3Taking people
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Where
Bydgoszcz, Gdansk, Konin, Lodz, Lublin, Poznan
Age
18 years and over
People
363 worldwide
Run by
OSE Immunotherapeutics
See details and how to joinNCT06472245
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Bydgoszcz, Gdansk, Otwock, Poznan, Wroclaw
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 2Taking people
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Where
Cracow, Lublin, Rzeszów, Torun, Warsaw
Age
18 years and over
People
243 worldwide
Run by
Shanghai Henlius Biotech
See details and how to joinNCT06907615 · EU 2025-523803-31-00
Phase 2Taking people
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Where
Gdansk, Koszalin, Poznan, Przemyśl, Warsaw
Age
18 years and over
People
180 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07221474 · EU 2025-520902-37-00
Phase 1/2Taking people
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Where
Gdansk, Koszalin, Warsaw
Age
18 years and over
People
140 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07286149 · EU 2024-512248-47-00
Phase 3Taking people
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Where
Brzozów, Gdansk, Lublin, Szczecin
Age
18 years and over
People
450 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00
Phase 3Taking people
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Where
Gdansk, Gliwice, Lodz, Lublin, Poznan, Warsaw
Age
18 years and over
People
714 worldwide
Run by
Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00
Phase 1Taking people
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
Where
Brzozów, Koszalin, Lublin, Olsztyn, Przemyśl
Age
18 years and over
People
40 worldwide
Run by
AstraZeneca
See details and how to joinNCT07391670 · EU 2025-521639-34-00
Phase 3Taking people
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Where
Gdansk, Lodz, Lublin, Poznan, Skorzewo, Warsaw
Age
18 years and over
People
780 worldwide
Run by
Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Where
Prabuty, Wieliszew
Age
18 years and over
People
182 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06855771 · EU 2024-519814-29-00
Phase 1/2Taking people
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Where
Otwock, Poznan, Przemyśl
Age
18 years and over
People
118 worldwide
Run by
MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07407933
Phase 3Taking people
Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
Where
Gdansk, Warsaw
Age
18 years and over
People
168 worldwide
Run by
Amgen Inc.
See details and how to join2026-525489-23-00 · EU 2026-525489-23-00
Phase 3Taking people
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
Where
Bialystok, Bydgoszcz, Elblag, Lodz, Olsztyn, Szczecin, Warsaw
Age
18 years and over
People
87 worldwide
Run by
Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00
Phase 3Taking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Lodz, Poznan, Rzeszów, Siedlce, Slupsk, Warsaw
Age
18 years and over
People
355 worldwide
Run by
Gilead Sciences Inc.
See details and how to join2024-515884-69-00 · EU 2024-515884-69-00
Phase 3Taking people
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Where
Bydgoszcz, Olsztyn, Poznan, Warsaw, Wilkowice
Age
18 years and over
People
582 worldwide
Run by
AstraZeneca
See details and how to joinNCT06350097 · EU 2023-509883-89-00
Phase 1/2Taking people
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Where
Gdansk, Katowice, Lublin, Poznan
Age
18 years and over
People
594 worldwide
Run by
BioNTech SE
See details and how to joinNCT06892548 · EU 2024-520238-31-01
Phase 1Taking people
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Where
Gdansk, Gliwice, Warsaw
Age
18 years to 99 years
People
160 worldwide
Run by
Amgen
See details and how to joinNCT07531095 · EU 2025-522888-15-00
Phase 1Taking people
A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours
Where
Gdansk, Lodz, Lublin, Wroc?aw
Age
18 years and over
People
138 worldwide
Run by
Deuteroncology
See details and how to join2023-504897-39-00 · EU 2023-504897-39-00
Phase 3Taking people
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
Where
Gdansk, Warsaw, Wilkowice
Age
18 years and over
People
156 worldwide
Run by
Amgen Inc.
See details and how to join2024-520050-38-00 · EU 2024-520050-38-00